Nyxoah (NASDAQ:NYXH) Price Target Cut to $17.00

Nyxoah (NASDAQ:NYXH) had its price target decreased by HC Wainwright from $18.00 to $17.00 in a report issued on Friday, Benzinga reports. HC Wainwright currently has a buy rating on the stock.

NYXH has been the subject of a number of other reports. Stifel Nicolaus lowered their price target on shares of Nyxoah from $27.00 to $19.00 and set a buy rating for the company in a report on Monday, June 24th. Cantor Fitzgerald decreased their price objective on shares of Nyxoah from $17.00 to $16.00 and set an overweight rating for the company in a research note on Wednesday, August 7th. Finally, Oppenheimer lowered their target price on Nyxoah from $15.00 to $13.00 and set an outperform rating for the company in a research note on Wednesday, August 7th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has an average rating of Buy and a consensus price target of $17.00.

Nyxoah Stock Down 1.0 %

Shares of NASDAQ NYXH opened at $9.50 on Friday. The company has a quick ratio of 5.16, a current ratio of 5.47 and a debt-to-equity ratio of 0.09. The stock has a market cap of $236.93 million, a PE ratio of -5.79 and a beta of 1.45. The business has a 50-day moving average price of $8.43 and a 200 day moving average price of $8.97. Nyxoah has a 52-week low of $4.00 and a 52-week high of $20.00.

Nyxoah (NASDAQ:NYXH) last issued its quarterly earnings results on Tuesday, August 6th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.45) by ($0.01). The firm had revenue of $0.83 million for the quarter, compared to analyst estimates of $1.93 million. Nyxoah had a negative return on equity of 42.00% and a negative net margin of 908.32%. Equities research analysts forecast that Nyxoah will post -1.91 earnings per share for the current year.

Hedge Funds Weigh In On Nyxoah

A number of institutional investors have recently bought and sold shares of the stock. CVI Holdings LLC purchased a new stake in Nyxoah in the 2nd quarter worth approximately $1,292,000. Ikarian Capital LLC bought a new position in Nyxoah in the 1st quarter worth $684,000. Finally, Iron Triangle Partners LP acquired a new position in shares of Nyxoah during the 1st quarter worth about $3,413,000.

About Nyxoah

Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.